428 related articles for article (PubMed ID: 29938565)
1. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
Noorani T; Garcia-Romeu A; Swift TC; Griffiths RR; Johnson MW
J Psychopharmacol; 2018 Jul; 32(7):756-769. PubMed ID: 29938565
[TBL] [Abstract][Full Text] [Related]
2. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu A; Griffiths RR; Johnson MW
Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of psilocybin-facilitated smoking cessation.
Johnson MW; Garcia-Romeu A; Griffiths RR
Am J Drug Alcohol Abuse; 2017 Jan; 43(1):55-60. PubMed ID: 27441452
[TBL] [Abstract][Full Text] [Related]
4. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.
Johnson MW; Garcia-Romeu A; Johnson PS; Griffiths RR
J Psychopharmacol; 2017 Jul; 31(7):841-850. PubMed ID: 28095732
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Johnson MW; Garcia-Romeu A; Cosimano MP; Griffiths RR
J Psychopharmacol; 2014 Nov; 28(11):983-92. PubMed ID: 25213996
[TBL] [Abstract][Full Text] [Related]
6. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
Johnson MW
Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
[TBL] [Abstract][Full Text] [Related]
7. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
Turton S; Nutt DJ; Carhart-Harris RL
Curr Drug Abuse Rev; 2014; 7(2):117-27. PubMed ID: 25563444
[TBL] [Abstract][Full Text] [Related]
8. The hidden therapist: evidence for a central role of music in psychedelic therapy.
Kaelen M; Giribaldi B; Raine J; Evans L; Timmerman C; Rodriguez N; Roseman L; Feilding A; Nutt D; Carhart-Harris R
Psychopharmacology (Berl); 2018 Feb; 235(2):505-519. PubMed ID: 29396616
[TBL] [Abstract][Full Text] [Related]
9. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Lea T; Amada N; Jungaberle H; Schecke H; Klein M
Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
[TBL] [Abstract][Full Text] [Related]
10. Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications.
O'Callaghan C; Hubik DJ; Dwyer J; Williams M; Ross M
J Music Ther; 2020 Jul; 57(3):282-314. PubMed ID: 32227084
[TBL] [Abstract][Full Text] [Related]
11. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
12. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
[TBL] [Abstract][Full Text] [Related]
13. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
[TBL] [Abstract][Full Text] [Related]
14. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
[TBL] [Abstract][Full Text] [Related]
15. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
J Psychopharmacol; 2022 Jan; 36(1):74-84. PubMed ID: 34189985
[TBL] [Abstract][Full Text] [Related]
16. Case analysis of long-term negative psychological responses to psychedelics.
Bremler R; Katati N; Shergill P; Erritzoe D; Carhart-Harris RL
Sci Rep; 2023 Sep; 13(1):15998. PubMed ID: 37749109
[TBL] [Abstract][Full Text] [Related]
17. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.
Lyons T; Carhart-Harris RL
J Psychopharmacol; 2018 Jul; 32(7):811-819. PubMed ID: 29338538
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
[TBL] [Abstract][Full Text] [Related]
19. Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis.
Crowe M; Manuel J; Carlyle D; Lacey C
Int J Ment Health Nurs; 2023 Aug; 32(4):1025-1037. PubMed ID: 36779424
[TBL] [Abstract][Full Text] [Related]
20. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Barrett FS; Johnson MW; Griffiths RR
J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
